acute myeloid leukemia

[Kronos Bio, Inc.] Kronos Bio, Inc. announced the US FDA has cleared its Investigational New Drug Application for LANRA, allowing the company to proceed with a Phase I/II clinical trial of LANRA in patients with relapsed or refractory FLT3-mutated AML in combination with gilteritinib.

[Cancer Discovery] Scientists demonstrated that an oncogenic mutant form of NPM1 (NPM1c) impaired mitochondrial function. NPM1c also hampered formation of PML nuclear bodies, which are regulators of mitochondrial fitness and key senescence effectors.

[Magenta Therapeutics, Inc.] Magenta Therapeutics, Inc. announced that it has received a clinical hold letter from the US FDA related to its Investigational New Drug Application filed in June 2021 to initiate a Phase I/II clinical trial of MGTA-117 in patients with acute myeloid leukemia and myelodysplastic syndrome.

[Leukemia] Researchers describe the immunological features of the acute myeloid leukemia (AML) niche, with particular attention to the crosstalk between the AML blasts and the cellular components of the altered tumor microenvironment and the mechanisms of immune escape that hamper the therapeutic effects of the most advanced treatments.

[Oncogenesis] The authors identified that guanylate-binding protein (GBP)1 and GBP2 interacted with MCL-1, the key prosurvival member of the BCL-2 family, via its BH3 domain. GBPs induced caspase-dependent apoptosis in chronic myeloid leukemia and acute myeloid leukemia cells, where the proapoptotic BCL-2 member, BAK, was an indispensable mediator.

[Blood] Researchers introduced sialic-acid-binding immunoglobulin-like lectin (Siglec)-6 as a novel target for CAR T-cells in acute myeloid leukemia (AML) and found that Siglec-6 was prevalently expressed on AML cell lines and primary AML blasts, including the subpopulation of AML stem cells.